Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30163514 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 | |
| SCHEMBL31429081 | 0.85 | MAPT (0.53) | NPC1RAB9AALDH1A1KMT2AMAPT | |
| SCHEMBL31428917 | 0.83 | MAPT (0.52) | NPC1RAB9AALDH1A1KMT2AMAPT | |
| SCHEMBL31428656 | 0.82 | MAPT (0.54) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 | |
| SCHEMBL30163547 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 | |
| SCHEMBL31428792 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 | |
| SCHEMBL31428963 | 0.80 | MAPT (0.53) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 | |
| SCHEMBL30163485 | 0.80 | MAPT (0.53) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 | |
| SCHEMBL31428829 | 0.80 | KDM4E (0.58) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 | |
| SCHEMBL31428575 | 0.80 | MAPT (0.43) | ALDH1A1KMT2AMAPTTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | LRRK2 532/4885NPC1 3237/4885RAB9A 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.